PROCEPT BioRobotics (PRCT)
NASDAQ:PRCT
Want to see PRCT full AI Analyst Report?
PRCT Stock Chart & Stats
$25.14
-$0.85(-0.97%)
At close: 4:00 PM EST
$25.14
-$0.85(-0.97%)
Day’s Range― - ―
52-Week Range$19.35 - $66.85
Previous CloseN/A
Volume113.34K
Average Volume (3M)1.45M
Market Cap
$1.40B
Enterprise Value$1.21B
Total Cash (Recent Filing)$245.64M
Total Debt (Recent Filing)$51.66M
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Jul 30, 2026EPS Estimate
-0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.82
Shares Outstanding56,909,412
10 Day Avg. Volume1,224,706
30 Day Avg. Volume1,453,177
Financial Highlights & Ratios
PEG Ratio10.67
Price to Book (P/B)4.78
Price to Sales (P/S)5.67
P/FCF Ratio-29.95
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue3.75
Enterprise Value/Gross Profit5.95
Enterprise Value/Ebitda-11.80
Forecast
1Y Price Target
$36.50Price Target Upside45.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)-1.54
Revenue Forecast (FY)$396.10M
Bulls Say, Bears Say
Bulls Say
Clinical DifferentiationClinical data showing Aquablation delivers superior urinary outcomes and lower rates of irreversible complications versus newer stent options may shift physician preference toward the procedure and help drive procedure volume growth.
Guideline EndorsementUpdated European urology guidelines give Aquablation a strong recommendation as an alternative to traditional surgery for patients seeking ejaculatory function preservation, which could facilitate wider clinical adoption and support improved reimbursement discussions.
Profitability LeverageManagement expects margins to expand as revenue shifts toward higher-margin procedure and recurring sales, supported by disciplined handpiece pricing and next-generation upgrades, potentially improving long-term profitability.
Bears Say
Balance-sheet ExposurePlans to offer operating leases to customers increase capital deployment and balance-sheet exposure, raising financial risk if customer adoption and utilization do not accelerate as assumed.
Competitive PressureLess invasive stent alternatives that preserve sexual function could attract patients and physicians away from Aquablation, reducing potential market share in the mid-range prostate treatment segment.
Operational ExecutionRecent commercial overhauls, de-stocking and execution challenges that reduced reported sales have impaired guidance credibility and may require multiple quarters of stronger results to regain investor trust.
PROCEPT BioRobotics News
PRCT FAQ
What was PROCEPT BioRobotics’s price range in the past 12 months?
PROCEPT BioRobotics lowest stock price was $19.35 and its highest was $66.85 in the past 12 months.
What is PROCEPT BioRobotics’s market cap?
PROCEPT BioRobotics’s market cap is $1.40B.
When is PROCEPT BioRobotics’s upcoming earnings report date?
PROCEPT BioRobotics’s upcoming earnings report date is Jul 30, 2026 which is in 87 days.
How were PROCEPT BioRobotics’s earnings last quarter?
PROCEPT BioRobotics released its earnings results on Apr 29, 2026. The company reported -$0.56 earnings per share for the quarter, beating the consensus estimate of -$0.563 by $0.003.
Is PROCEPT BioRobotics overvalued?
According to Wall Street analysts PROCEPT BioRobotics’s price is currently Undervalued.
Does PROCEPT BioRobotics pay dividends?
PROCEPT BioRobotics does not currently pay dividends.
What is PROCEPT BioRobotics’s EPS estimate?
PROCEPT BioRobotics’s EPS estimate is -0.46.
How many shares outstanding does PROCEPT BioRobotics have?
PROCEPT BioRobotics has 56,909,412 shares outstanding.
What happened to PROCEPT BioRobotics’s price movement after its last earnings report?
PROCEPT BioRobotics reported an EPS of -$0.56 in its last earnings report, beating expectations of -$0.563. Following the earnings report the stock price went up 10.732%.
Which hedge fund is a major shareholder of PROCEPT BioRobotics?
Currently, no hedge funds are holding shares in PRCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PROCEPT BioRobotics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$36.50 (45.19% Upside)
$36.50 (45.19% Upside)
Blogger Sentiment
Bullish
PRCT Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 7.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $10.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.1%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.59%
12-Months-Change
Fundamentals
Return on Equity
-27.70%
Trailing 12-Months
Asset Growth
-6.22%
Trailing 12-Months
Company Description
PROCEPT BioRobotics
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
PRCT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally positive operational and commercial trajectory: robust top‑line growth (20% revenue; ~30% procedure growth), margin expansion to management targets (65% gross margin), pricing discipline and meaningful clinical/regulatory wins (EAU guideline upgrade, FDA clearance). These positives are balanced against higher operating expenses, larger GAAP and adjusted EBITDA losses in Q1, tariff headwinds and short‑term disruption from a commercial realignment that push some benefits into the back half of 2026. Management reaffirmed full‑year guidance while taking a prudent near‑term stance, expecting improved leverage and positive EBITDA in Q4.View all PRCT earnings summariesPRCT Stock 12 Month Forecast
Average Price Target
$36.50
▲(45.19% Upside)
Technical Analysis
Alphatec Holdings
―
Artivion
―
LivaNova
―
Inspire Medical Systems
―
SS Innovations International
―
Ownership Overview
4.11% Insiders
28.77% Mutual Funds
5.92% Other Institutional Investors
46.40% Public Companies and
Individual Investors